Acute Labetalol Use in Preeclampsia

PHASE4TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 18, 2019

Primary Completion Date

July 20, 2020

Study Completion Date

July 20, 2020

Conditions
Preeclampsia With Severe Features
Interventions
DRUG

Experimental labetalol dose

Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.

OTHER

Current standard of care

Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the standard dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.

Trial Locations (1)

12208

Albany Medical Center Obstetrics and Gynecology, Albany

Sponsors
All Listed Sponsors
lead

Albany Medical College

OTHER